SCHEMBL765957

SCHEMBL765957

CC1Cc2ccccc2O1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.50
CREBBP Q92793 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
MAOA P21397 8/20 0.46
MAOB P27338 8/20 0.46
CHRM2 P08172 2/20 0.44
CHRM4 P08173 2/20 0.44
CHRM5 P08912 2/20 0.44
CHRM1 P11229 2/20 0.44
CHRM3 P20309 2/20 0.44
PARP1 P09874 3/20 0.43
AOC2 O75106 5/20 0.41
DAO P14920 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8471197 1.00 BRD4 (0.50) BRD4CREBBPTDP1MAOAMAOB
SCHEMBL8470150 1.00 BRD4 (0.50) BRD4CREBBPTDP1MAOAMAOB
SCHEMBL11381215 0.78 MAOA (0.37) BRD4CREBBPMAOAMAOBCHRM2
SCHEMBL799675 0.78 CA2 (0.44) BRD4CREBBPCHRM2CHRM4CHRM5
SCHEMBL16429469 0.78 CA2 (0.44) BRD4CREBBPCHRM2CHRM4CHRM5
SCHEMBL8504530 0.78 CHRM2 (0.41) BRD4CREBBPMAOAMAOBCHRM2
SCHEMBL155647 0.78 CA2 (0.44) BRD4CREBBPCHRM2CHRM4CHRM5
SCHEMBL17167266 0.78 CA2 (0.44) BRD4CREBBPCHRM2CHRM4CHRM5
SCHEMBL7313976 0.75 AOC2 (0.41) BRD4CREBBPMAOAMAOBCHRM2
SCHEMBL8507467 0.75 NISCH (0.42) BRD4CREBBPTDP1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108475728-B Composition for manufacturing organic semiconductor device 株式会社大赛璐 2023-04-18 CN claimed
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS LIBRA THERAPEUTICS, INC. 2023-01-12 US claimed
CN-112760109-A Method for comprehensively utilizing waste computer circuit boards through microwave pyrolysis 楚雄滇中有色金属有限责任公司 2021-05-07 CN claimed
US-10717886-B2 Ink composition, method for producing organic semiconductor element, organic semiconductor device, and method for producing optical element SEIKO EPSON CORPORATION (JP) 2020-07-21 US claimed
CN-105659404-B Solvent for manufacturing organic transistor 株式会社大赛璐 2020-02-07 CN claimed
CN-109516923-A Compounds and organic luminescent device comprising it 东进世美肯株式会社 2019-03-26 CN claimed
CN-105017188-B A method of synthesis 3- halogen methyl -2,3- Dihydrobenzofuranes class compound 福州大学 2019-03-05 CN claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20190006603-A1 COMPOSITION FOR MANUFACTURING ORGANIC SEMICONDUCTOR DEVICE DAICEL CORPORATION (JP) 2019-01-03 US claimed
EP-3396727-A1 COMPOSITION FOR MANUFACTURING ORGANIC SEMICONDUCTOR DEVICE Daicel Corporation (JP) 2018-10-31 EP claimed
CN-108475728-A Composition for manufacturing organic semiconductor device 株式会社大赛璐 2018-08-31 CN claimed
US-20180030296-A1 INK COMPOSITION, METHOD FOR PRODUCING ORGANIC SEMICONDUCTOR ELEMENT, ORGANIC SEMICONDUCTOR DEVICE, AND METHOD FOR PRODUCING OPTICAL ELEMENT SEIKO EPSON CORPORATION (JP) 2018-02-01 US claimed
EP-2488510-B1 Amides and thioamides as pest control agents BAYER IP GMBH (DE) 2017-03-29 EP claimed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US claimed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP claimed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US claimed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP claimed
WO-2008118758-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (GB) 2008-10-02 WO claimed
CN-1047595-C Aminocoumaran derivatives, process for their preparation and their use as medicaments TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1999-12-22 CN claimed
WO-1998002435-A1 NOVEL BENZODIOXANES AND 1-(2H)-BENZOPYRANES, THEIR PREPARATION AND THEIR USE AS MEDICINE PIERRE FABRE MEDICAMENT (FR) 1998-01-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 BRD4 835/4885CREBBP 2883/4885TDP1 4420/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 BRD4 835/4885CREBBP 2883/4885TDP1 4420/4885
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS TRPM7, TRPM2, TRPM5 BRD4 2202/4885CREBBP 3232/4885TDP1 3364/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR BRD4 4882/4885CREBBP 4114/4885TDP1 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.